Clinical Trial Search

Primary: Percentage of Triglyceride (TG) Change — -38.12 percentage of TG change

Primary: Reduction of LDL Cholesterol Levels — -39.45; -29.13 percent change of LDL — p=0.0013

Primary: Percent Change From Baseline in LDL-C at Week 6 — -26.7; -12.8 Percent Change — p=<0.001

Primary: Changes Serum Triglyceride Levels — 223.1; 241.2; 227.0; 267.2 mg/dl — p=0.0001

Primary: Total Cholesterol Before and After Simvastatin/Ezetimibe Administration — 255; 253; 180; 215 mg/dl — p=<0.05

Primary: Percent Changes From Baseline to End-of-treatment in Non-HDL Cholesterol, HDL Cholesterol, and Triglycerides by LCP-AtorFen Versus Atorvastatin Monotherapy — -44.8…

Primary: Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) (Phase I) — -24.8; -10.1; -13.8 Percentage Change — p=<0.001

Primary: Percent Change From Baseline to 12 Weeks Endpoint in High Density Lipoprotein Cholesterol (HDL-C) With LY2484595 in Combination With Atorvastatin and Atorvastatin…

Primary: Percent Change From Baseline in Low Density Lipoprotein (LDL-C) at Week 6 — -36.5; -49.6; -39.4; -53.9 Percent Change — p=<0.001

Primary: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Endpoint, After 6 Weeks of Treatment — -32.2; -20.8 percentage change — p=0.005

Primary: Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 12 — 1.0; -54.9 percent change — p=<0.001

Primary: Number of LDLR Gene Mutations — 7 gene mutations

Primary: Percent Change From Baseline to Week 6 in Low-Density Lipoprotein (LDL)-C — -27.4; -11.0 Percent Change — p=<0.001

Primary: Percentage of Participants Achieving Target Lipid Values — 46.8 Percentage of participants

Primary: Percent Change From Baseline in Low Density Lipoprotein Cholesterol at Week 12 — -10.0; -5.5 Percent — p=0.006

Primary: Total Cholesterol (TC) Levels at First Acute Coronary Event — 163.5 mg/dL

Primary: Change From Baseline in Direct LDL-C at Week 8 — -2.0; -1.5; -4.2; 0.2 Percent change — p=0.06

Primary: Effect of Fixed-Dose Combination (FDC) Compared to Placebo on LDL-C — -45.58; 3.03 percent change from baseline — p=<.0001

Primary: Percent Change From Baseline for Apolipoprotein B (ApoB) at Day 180 — -11.6; -14.1; -24.3; -19.0 Percent change — p=0.691

Primary: Triglycerides After 90 Days — 2.3; 1.1; 1.3 mmol/L

Primary: Changes in LDL Cholesterol — -0.83; -1.47; -0.93; -0.32 mmol/L

Primary: Percent Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) at Week 12 — 1.0; -55.6 percent change — p=<0.001

Primary: Change in Intestinal mRNA Expression Levels of LDL Receptor Between the Two 12-week Interventions — 110531; 95140 #copies/100000 copies housekeeping gene

Primary: Percentage Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) — -44.6; -46.9; -48.9; -50.4 Percentage Change

Primary: Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After 6 Weeks Combination Treatment — -59.7200; -63.4800; -55.2200; -57.4200 Percentage

Primary: Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 12 — -0.8; -50.8 percent change — p=<0.001

Primary: Number of Participants With Adverse Events and Adverse Reactions — 141; 61 Participants

Primary: LDL Goal Attainment — 6; 6; 9 participants

Primary: Number of Subjects Experiencing Treatment-Emergent Adverse Events (TEAEs) — 109 Participants

Primary: Change in Blood LDL Cholesterol Level — -32.48; 2.54 mg/dL — p=<0.0001